INSM News and Press, Insmed Inc. From 05/27/24

Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis PR Newswire —Conference Call to Take Place Tomorrow, Tuesday, May 28, 2024 , at 8:00 am ET— BRIDGEWATER, N.J. , M...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-22 17:10:41 ET Gainers: Chicken Soup for the Soul  ( CSSEN ) +18% . Signature Bank ( OTC:SBNY ) +7% . PetMed Express ( PETS ) +6% . Prime Medicine ( PRME ) +6% . Sana Biotechnology ( SANA ) +5% . Losers: Cyto...

Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session PR Ne...

2024-05-09 16:29:09 ET Insmed, Inc. (INSM) Q1 2024 Earnings Conference Call May 09, 2024, 08:00 ET Company Participants Bryan Dunn - Executive Director, Investor Relations William Lewis - Chairman, President & CEO Eugene Sullivan - Chief Product Strategy Offi...

2024-05-09 07:47:57 ET More on Insmed Seeking Alpha’s Quant Rating on Insmed Historical earnings data for Insmed Financial information for Insmed Read the full article on Seeking Alpha For further details see: Insmed reports mixed Q1 result...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update PR Newswire — ARIKAYCE ® (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual Growth Over the First Qua...

2024-05-08 11:21:46 ET More on Insmed Insmed Incorporated (INSM) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Insmed Historical earnings data for Insmed Financial information for Insmed Read the full article on Seeking Alp...

Insmed To Present at the BofA Securities Health Care Conference 2024 PR Newswire BRIDGEWATER, N.J. , May 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with seriou...